Clinic Software← All companies
Onc.AI
AI-powered technology bringing clarity to cancer treatment
health AIdigital healthmedtech
StageSeries A
Raised$33.96M
Founded2020
Employees20
LocationSan Carlos, CA
Business modelB2B, SaaS
About
Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans.
Product
- Value proposition
- Leverages real-world oncology data and AI to assist pharma and clinicians in decision-making across oncology, including predictive/prognostic models and FDA-designated breakthroughs.
- Target customers
- pharma companies, clinical researchers, oncology care teams
- Pricing
- not publicly disclosed
- Regulatory
- FDA Breakthrough Device Designation (for Serial CT/Score model)
Founders
- Akshay Nanduri — CEO and Co-Founder
- Salmaan Ahmed — VP of Software and Co-Founder
Categories
Products
Onclara EvaluateOnclara IOOnclara platform
Key features
predictive and prognostic AI models for oncologyreal-world dataset trainingFDA Breakthrough Device-designated modelsclinical decision support for trial design and treatment decisionsimaging- and radiomics-informed analytics
Technologies
AI/MLradiomicsdeep learningreal-world data (RWD)clinical decision supportpredictive modeling
Integrations
electronic health records (EHR)clinical trial data systemspharma data platformspotential interoperability with hospital IT systems
Target conditions
cancermetastatic NSCLConcology indications
Care settings
pharma R&Dhospital/clinicclinical trialsvirtual/remote collaboration
Certifications
FDA Breakthrough Device Designation (for specific models)
Notable customers
pharma companies (unspecified)
Partnerships
BusinessWire press releases with technology milestones (unspecified partners)research/insights partnerships (Decibio interview)
Awards
FDA Breakthrough Device Designation (for Serial CT Score)NCI grant award (2M) for AI-based clinical decision support for metastatic NSCLC)
Traction metrics
Series A $25M financingFDA Breakthrough Device DesignationNCI grant for metastatic NSCLC
Investors
National Cancer InstituteAccompliceThe Blue Venture FundDigitalis VenturesKdT VenturesMassMutualAction Potential Venture CapitalDavid Diaz-CasariegoEmir SandhuLifeX VenturesJohn CapodilupoThomas HawesJonathan FlemingStanley MarksT. Chen Fong
News
- Onc.AI Awarded FDA Breakthrough Device Designation for Serial CT Response Score Deep Learning Model · 2025-02-06T00:00:00.000Z
- Onc.AI Lung Clinical Management validated in real-world dataset and Pfizer clinical trial - onc.ai · 2025-02-05T15:24:29.000Z
- Onc.AI to Present Breakthrough Deep Learning Radiomic Biomarker Results at 2025 ASCO Annual Meeting · 2025-05-30T10:03:00.000Z
- Onc.AI Awarded $2 Million National Cancer Institute Grant to Advance AI-based Clinical Decision Support for Metastatic NSCLC · 2024-10-24T00:00:00.000Z
- Onc.AI Announces Positive External Validation of Onclara IO, a CT Imaging AI Biomarker for First-Line Immunotherapy in PD-L1-High Metastatic Non-Small Cell Lung Cancer | Morningstar · 2026-05-28T11:00:00.000Z
- Onc.AI's lung cancer analysis tool gets FDA Breakthrough Device Designation - Mugglehead Investment Magazine · 2025-02-12T00:21:55.000Z
